Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma.
Weinhold N et al. Haematologica. 2015 Nov 26. pii: haematol.2015.136929. [Epub ahead of print].

Mechanisms for autophagy modulation by isoprenoid biosynthetic pathway inhibitors in multiple myeloma cells.
Dykstra KM et al. Oncotarget. 2015 Nov 22. doi: 10.18632/oncotarget.6365. [Epub ahead of print].

The role of circulating miRNAs in multiple myeloma.
Zhang J et al. Sci China Life Sci. 2015 Nov 25. [Epub ahead of print

EZH2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes.
Hernando H et al. Mol Cancer Ther. 2015 Nov 20. pii: molcanther.0486.2015. [Epub ahead of print].

Marrow Infiltrating Lymphocytes: Their Role in Adoptive Immunotherapy.
Noonan KA et al. Cancer J. 2015 Nov-Dec;21(6):501-5. doi: 10.1097/PPO.0000000000000159

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment ofMultiple Myeloma in a Preclinical Model.
Fichou N et al. Front Med (Lausanne). 2015 Nov 4;2:76.

Erythrophagocytosis in a cyclin D1 positive plasma cell myeloma with near-tetraploid karyotypic abnormalities and cryptic MYC/IGH fusion.
Galeotti J et al. Ann Hematol. 2015 Nov 16. [Epub ahead of print].

A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.
Erickson SW et al. Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13830. [Epub ahead of print].

Discovery of a First-in-Class, Potent, Selective and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083).
Zhou HJ et al. J Med Chem. 2015 Nov 13. [Epub ahead of print].

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J et al. Oncotarget. 2015 Nov 2. doi: 10.18632/oncotarget.6083. [Epub ahead of print].

Upregulation of CCL2 via ATF3/c-Jun interaction mediated the Bortezomib-induced peripheral neuropathy.
Liu C et al. Brain Behav Immun. 2015 Nov 10. pii: S0889-1591(15)30049-0. doi: 10.1016/j.bbi.2015.11.004. [Epub ahead of print].

Protein C-terminal enzymatic labeling identifies novel caspase cleavages during the apoptosis of multiple myeloma cells induced by kinase inhibition.
Duan W et al. Proteomics. 2015 Nov 10. doi: 10.1002/pmic.201500356. [Epub ahead of print].

The Proteasome Inhibitor, Bortezomib, Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.
Toscani D et al. J Bone Miner Res. 2015 Nov 9. doi: 10.1002/jbmr.2741. [Epub ahead of print].

Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R et al. BMC Cancer. 2015 Nov 6;15:864. doi: 10.1186/s12885-015-1892-7.

A 13 mer LNA-i-miR-221 inhibitor restores drug-sensitivity in melphalan-refractory multiple myeloma cells.
Gulla’ A et al. Clin Cancer Res. 2015 Nov 2. pii: clincanres.0489.2015. [Epub ahead of print].

The clinical value of molecular subtyping multiple myeloma using gene expression profiling.
Weinhold N et al. Leukemia. 2015 Nov 3. doi: 10.1038/leu.2015.309. [Epub ahead of print].

Identification of a novel compound (β-sesquiphellandrene) from turmeric (Curcuma longa) with anticancer potential: comparison with curcumin.
Tyagi AK et al. Invest New Drugs. 2015 Dec;33(6):1175-86. doi: 10.1007/s10637-015-0296-5. Epub 2015 Nov 2.

Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.
Wenzl K et al. Tumour Biol. 2015 Oct 31. [Epub ahead of print].

Synthesis and evaluation of 2-alkylthio-4-(N-substituted sulfonamide)pyrimidine hydroxamic acids as anti-myeloma agents.
Xiang J et al. Chem Biol Drug Des. 2015 Oct 30. doi: 10.1111/cbdd.12678. [Epub ahead of print].

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?
Chretien ML et al. Blood. 2015 Oct 29. pii: blood-2015-06-650242. [Epub ahead of print].

Fibronectin on the surface of myeloma cell-derived exosomes mediates exosome-cell interactions.
Purushothaman A et al. J Biol Chem. 2015 Nov 24. pii: jbc.M115.686295. [Epub ahead of print]